Kulkarni HR - Search Results

1

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. Schuchardt C, et al. Among authors: kulkarni hr. Recent Results Cancer Res. 2013;194:519-36. doi: 10.1007/978-3-642-27994-2_30. Recent Results Cancer Res. 2013. PMID: 22918780

2

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, Kulkarni H, Haugvik SP, Hommann M, Baum RP. Kaemmerer D, et al. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1659-68. doi: 10.1007/s00259-011-1846-5. Epub 2011 May 31. Eur J Nucl Med Mol Imaging. 2011. PMID: 21626438

3

Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.

Baum RP, Kulkarni HR, Carreras C. Baum RP, et al. Among authors: kulkarni hr. Semin Nucl Med. 2012 May;42(3):190-207. doi: 10.1053/j.semnuclmed.2012.01.002. Semin Nucl Med. 2012. PMID: 22475428 Review.

4

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience.

Baum RP, Kulkarni HR. Baum RP, et al. Among authors: kulkarni hr. Theranostics. 2012;2(5):437-47. doi: 10.7150/thno.3645. Epub 2012 May 7. Theranostics. 2012. PMID: 22768024 Free PMC article.

5

High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT.

Kulkarni HR, Prasad V, Kaemmerer D, Hommann M, Baum RP. Kulkarni HR, et al. Recent Results Cancer Res. 2013;194:373-8. doi: 10.1007/978-3-642-27994-2_19. Recent Results Cancer Res. 2013. PMID: 22918769

6

Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors.

Carreras C, Kulkarni HR, Baum RP. Carreras C, et al. Among authors: kulkarni hr. Recent Results Cancer Res. 2013;194:379-84. doi: 10.1007/978-3-642-27994-2_20. Recent Results Cancer Res. 2013. PMID: 22918770

7

Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.

Kulkarni HR, Schuchardt C, Baum RP. Kulkarni HR, et al. Recent Results Cancer Res. 2013;194:551-9. doi: 10.1007/978-3-642-27994-2_32. Recent Results Cancer Res. 2013. PMID: 22918782

8

Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?

Kulkarni HR, Prasad V, Schuchardt C, Baum RP. Kulkarni HR, et al. Recent Results Cancer Res. 2013;194:561-6. doi: 10.1007/978-3-642-27994-2_33. Recent Results Cancer Res. 2013. PMID: 22918783

9

Vandetanib therapy in medullary thyroid cancer.

Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D. Grabowski P, et al. Among authors: kulkarni hr. Drugs Today (Barc). 2012 Nov;48(11):723-33. doi: 10.1358/dot.2012.48.11.1867323. Drugs Today (Barc). 2012. PMID: 23170308 Review.

10

Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

Budiawan H, Salavati A, Kulkarni HR, Baum RP. Budiawan H, et al. Among authors: kulkarni hr. Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):39-52. eCollection 2013. Am J Nucl Med Mol Imaging. 2013. PMID: 24380044 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters